Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Baumgart DC, et al. Among authors: buchman al. Inflamm Bowel Dis. 2010 Apr;16(4):620-9. doi: 10.1002/ibd.21084. Inflamm Bowel Dis. 2010. PMID: 19714757 Clinical Trial.
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Sands BE, et al. Among authors: buchman al. Gastroenterology. 1999 Jul;117(1):58-64. doi: 10.1016/s0016-5085(99)70550-0. Gastroenterology. 1999. PMID: 10381910 Clinical Trial.
Hyperbaric oxygen therapy for severe ulcerative colitis.
Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Buchman AL, et al. J Clin Gastroenterol. 2001 Oct;33(4):337-9. doi: 10.1097/00004836-200110000-00018. J Clin Gastroenterol. 2001. PMID: 11588553
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR; ISIS 2302-CS9 Investigators. Yacyshyn BR, et al. Among authors: buchman al. Gut. 2002 Jul;51(1):30-6. doi: 10.1136/gut.51.1.30. Gut. 2002. PMID: 12077088 Free PMC article. Clinical Trial.
Bones and Crohn's: problems and solutions.
Buchman AL. Buchman AL. Inflamm Bowel Dis. 1999 Aug;5(3):212-27. doi: 10.1097/00054725-199908000-00010. Inflamm Bowel Dis. 1999. PMID: 10453378 Review.
A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators. Dotan I, et al. Among authors: buchman al. Gut. 2010 Jun;59(6):760-6. doi: 10.1136/gut.2009.179994. Gut. 2010. PMID: 20551461 Clinical Trial.
205 results